PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT00810732
- Locations
- π¬π§
Clinical Research Centre and Pharmacology Unit, Edinburgh, Scotland, United Kingdom
π¬π§the University of Edinburgh, Western General Hospital, Department of Medical Sciences, Edinburgh, Scotland, United Kingdom
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2012-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1192
- Registration Number
- NCT00811018
- Locations
- π¬π§
Pfizer Investigational Site, Newcastle, United Kingdom
Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691
- Conditions
- Hepatitis C Virus
- Interventions
- Drug: PF-04878691 3mgDrug: PF-04878691 6mgDrug: PF-04878691 9mg
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00810758
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- Drug: SKI-606 (Bosutinib)
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 63
- Registration Number
- NCT00811070
- Locations
- π―π΅
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
π―π΅Tohoku University Hospital, Sendai-city, Miyagi, Japan
π―π΅Toyohashi Municipal Hospital, Aichi, Japan
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2720
- Registration Number
- NCT00809354
- Locations
- πΊπΈ
Perimeter Institute for Clinical Reseach, Inc., Atlanta, Georgia, United States
πΊπΈLaureate Clinical Research Group, Atlanta, Georgia, United States
πΊπΈOptimed Research, LTD, Columbus, Ohio, United States
The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 102
- Registration Number
- NCT00809328
- Locations
- π―π΅
Pfizer Investigational Site, Shiogama-city, Japan
Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia
- Conditions
- Postherpetic Neuralgia
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT00809679
Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers
- Conditions
- Fibromyalgia
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2011-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00809289
- Locations
- π§πͺ
Pfizer Investigational Site, Bruxelles, Belgium
Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00809536
- Locations
- πΈπ¬
Pfizer Investigational Site, Singapore, Singapore
Extension Study Of Tanezumab In Osteoarthritis
- Conditions
- Osteoarthritis
- Interventions
- Biological: tanezumab
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2147
- Registration Number
- NCT00809783
- Locations
- πΊπΈ
Laureate Clinical Research Group, Atlanta, Georgia, United States
πΊπΈArthritis and Rheumatology of Georgia, Atlanta, Georgia, United States
πΊπΈRehabilitation Institute of Chicago, Chicago, Illinois, United States